Marimed (MRMD) EBIAT (2016 - 2025)
Marimed (MRMD) has disclosed EBIAT for 15 consecutive years, with -$2.9 million as the latest value for Q3 2025.
- On a quarterly basis, EBIAT fell 197.07% to -$2.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$17.8 million, a 24.31% decrease, with the full-year FY2024 number at -$12.2 million, up 24.12% from a year prior.
- EBIAT was -$2.9 million for Q3 2025 at Marimed, down from -$1.4 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $7.5 million in Q2 2021 to a low of -$10.2 million in Q4 2023.
- A 5-year average of -$903736.8 and a median of -$990000.0 in 2024 define the central range for EBIAT.
- Peak YoY movement for EBIAT: surged 756.56% in 2021, then tumbled 307.54% in 2023.
- Marimed's EBIAT stood at -$6.6 million in 2021, then soared by 174.22% to $4.9 million in 2022, then crashed by 307.54% to -$10.2 million in 2023, then increased by 21.3% to -$8.0 million in 2024, then surged by 63.23% to -$2.9 million in 2025.
- Per Business Quant, the three most recent readings for MRMD's EBIAT are -$2.9 million (Q3 2025), -$1.4 million (Q2 2025), and -$5.5 million (Q1 2025).